As a Texas medical doctor and Transvaginal Mesh Attorney I am providing this information and commentary.
A number of lawsuits over Bard Avaulta mesh and other transvaginal products manufactured by C.R. Bard have been filed throughout the United States. The general allegations in these claims are that women experienced painful complications after receiving the vaginal mesh products for repair of pelvic organ prolapse (POP) and other gynecological and urological medical conditions.
Most recently, more than 100 people have filed a Bard Avaulta vaginal mesh lawsuit. At least 84 of the cases are filed in the federal court system, where they have been consolidated for as part of an MDL, or multidistrict litigation, before Judge Goodwin in the U.S. District Court for the Southern District of West Virginia. Another 37 cases have been filed in New Jersey state court, where the litigation has been centralized before Judge Higbee in Atantic County.
According to a case management order issued in the Bard Avaulta MDL, the next step of the litigation involves the selection of a pool of potential bellwether cases. In the order, Judge Goodwin indicated that the discovery process is not anticipated to begin before October.
Other products manufactured and sold by C.R. Bard have been included in the MDL and New Jersey state court litigation, including the Align, Pelvicol, Pelvilace, PelviSoft, Pelvitex, uretex and Ugytex mesh systems.
All of the complaints involve allegations that the transvaginal mesh products were defectively designed and that C.R. Bard failed to adequately research the risks associated with the mesh or warn about the risk of possible complications that can result in pain and disfigurement.
Bard vaginal slings have been associated with erosion of the mesh into the vagina, infection, recurrence of prolapse, urinary problems and painful sexual intercourse, among others complications. Awareness about the potential risk or transvaginal mesh problems has increased in recent weeks, following a warning issued by the FDA last month.
In July 2011, the FDA issued a statement indicating that they have been unable to find any evidence that Bard Avaulta mesh and other transvaginal mesh systems for repair of pelvic organ prolapse provide any significant benefits over other available means of treatment. More than 1,500 reports of complications with vaginal mesh products, such as the Bard Avaulta Mesh and other similar systems, have been received by the FDA over the past three years